AIMS: We determined whether c-kit proto-oncogene is expressed in prostate cancer and whether its expression is related with biochemical relapse in high risk localized prostate cancer patients. METHODS: c-Kit expression was evaluated by immuno-histochemistry in 94 prostate cancer samples from patients treated by radical prostatectomy followed by adjuvant hormonal therapy because all patients had a pT3a stage (initially cT2 stage). All patients presented a >7 Gleason score and a >10 pre-operative PSA value. We evaluated association between c-kit positive staining and disease free survival. RESULTS: In 26 of 94 prostate cancer, we found an epithelial positive c-kit expression. The epithelial expression was found in the peripheral zone of prostate tissue. 13/94 relapsed and, although not statistically significant (p 0.055), a trend to a higher risk of relapse among the c-kit positive samples was observed in our series of prostate cancer patients. CONCLUSIONS: Our study is only an initial experience and it is necessary to consider a higher number of patients to clarify whether c-kit is really an independent predictor for disease recurrence. Further study in this area will help to understand whether anti c-kit drugs could become an effective complement to the armamentarium of prostate cancer therapies.
AIMS: We determined whether c-kit proto-oncogene is expressed in prostate cancer and whether its expression is related with biochemical relapse in high risk localized prostate cancerpatients. METHODS:c-Kit expression was evaluated by immuno-histochemistry in 94 prostate cancer samples from patients treated by radical prostatectomy followed by adjuvant hormonal therapy because all patients had a pT3a stage (initially cT2 stage). All patients presented a >7 Gleason score and a >10 pre-operative PSA value. We evaluated association between c-kit positive staining and disease free survival. RESULTS: In 26 of 94 prostate cancer, we found an epithelial positive c-kit expression. The epithelial expression was found in the peripheral zone of prostate tissue. 13/94 relapsed and, although not statistically significant (p 0.055), a trend to a higher risk of relapse among the c-kit positive samples was observed in our series of prostate cancerpatients. CONCLUSIONS: Our study is only an initial experience and it is necessary to consider a higher number of patients to clarify whether c-kit is really an independent predictor for disease recurrence. Further study in this area will help to understand whether anti c-kit drugs could become an effective complement to the armamentarium of prostate cancer therapies.
Authors: Jian-Hua Guo; Juan Zhou; Yang Zhao; Peng-Yue Liu; Hai-Jun Yao; Jun Da; Ming Zhang; Zhe Zhou; Qi Chen; Yu-Bing Peng; Zhong Wang Journal: Am J Transl Res Date: 2015-03-15 Impact factor: 4.060
Authors: Christoph Wiesner; Sanaa M Nabha; Emanuel Burck Dos Santos; Hamilto Yamamoto; Hong Meng; Sebastian W Melchior; Fernando Bittinger; Joachim W Thüroff; Robert L Vessella; Michael L Cher; R Daniel Bonfil Journal: Neoplasia Date: 2008-09 Impact factor: 5.715
Authors: Bethany A Kerr; Ranko Miocinovic; Armine K Smith; Xiaoxia Z West; Katherine E Watts; Amanda W Alzayed; Joseph C Klink; Maria C Mir; Tiffany Sturey; Donna E Hansel; Warren D Heston; Andrew J Stephenson; Eric A Klein; Tatiana V Byzova Journal: Oncotarget Date: 2015-01-30